Literature DB >> 9453127

Effect of dual-subtype vaccine against feline immunodeficiency virus infection.

T Hohdatsu1, S Okada, K Motokawa, C Aizawa, J K Yamamoto, H Koyama.   

Abstract

Dual-subtype feline immunodeficiency virus (FIV) vaccine, consisting of inactivated cells infected with subtypes A (Petaluma strain) and D (Shizuoka strain), was developed and tested for its vaccine efficacy against FIV infection in specific pathogen free (SPF) cats. Animals were monitored for proviral DNA by FIV-specific PCR and for FIV-specific antibody profiles by ELISA and virus-neutralization assays. In addition, blood from challenged cats was inoculated into naive SPF cats to confirm the viral status of the vaccinated cats. All cats immunized with Petaluma vaccine alone were protected against homologous Petaluma challenge, but only one of four cats was protected against heterologous Shizuoka challenge. More importantly, all cats immunized with the dual-subtype vaccine were protected against both Petaluma and Shizuoka challenges. These results suggest that a multi-subtype vaccine approach may provide the broad-spectrum immunity necessary for vaccine protection against strains from different subtypes.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9453127      PMCID： PMC7117228          DOI： 10.1016/s0378-1135(97)00164-8

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN： 0378-1135            Impact factor:   3.293


  38 in total

1.  Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity.

Authors:  N E Byars; A C Allison
Journal:  Vaccine       Date:  1987-09       Impact factor: 3.641

2.  Feline immunodeficiency virus vaccination: characterization of the immune correlates of protection.

Authors:  M J Hosie; J N Flynn
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

3.  Protection against homologous but not heterologous challenge induced by inactivated feline immunodeficiency virus vaccines.

Authors:  M J Hosie; R Osborne; J K Yamamoto; J C Neil; O Jarrett
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

4.  Vaccination against feline immunodeficiency virus using fixed infected cells.

Authors:  E J Verschoor; A L van Vliet; H F Egberink; W Hesselink; W E van Alphen; I Joosten; C J Boog; M C Horzinek; A de Ronde
Journal:  Vet Immunol Immunopathol       Date:  1995-05       Impact factor: 2.046

5.  Protection of neonatal kittens against feline immunodeficiency virus infection with passive maternal antiviral antibodies.

Authors:  R Pu; S Okada; E R Little; B Xu; W V Stoffs; J K Yamamoto
Journal:  AIDS       Date:  1995-03       Impact factor: 4.177

Review 6.  Simian and feline immunodeficiency viruses: animal lentivirus models for evaluation of AIDS vaccines and antiviral agents.

Authors:  M B Gardner
Journal:  Antiviral Res       Date:  1991-05       Impact factor: 5.970

7.  Induction of feline immunodeficiency virus-specific cytolytic T-cell responses from experimentally infected cats.

Authors:  W Song; E W Collisson; P M Billingsley; W C Brown
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

8.  Involvement of gag- and env-specific cytotoxic T lymphocytes in protective immunity to feline immunodeficiency virus.

Authors:  J N Flynn; J A Beatty; C A Cannon; E B Stephens; M J Hosie; J C Neil; O Jarrett
Journal:  AIDS Res Hum Retroviruses       Date:  1995-09       Impact factor: 2.205

9.  Immunologic abnormalities in pathogen-free cats experimentally infected with feline immunodeficiency virus.

Authors:  C D Ackley; J K Yamamoto; N Levy; N C Pedersen; M D Cooper
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

10.  Identification of three feline immunodeficiency virus (FIV) env gene subtypes and comparison of the FIV and human immunodeficiency virus type 1 evolutionary patterns.

Authors:  D L Sodora; E G Shpaer; B E Kitchell; S W Dow; E A Hoover; J I Mullins
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103
View more
  14 in total

1.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: reevaluation of neutralizing antibody levels elicited by a protective and a nonprotective vaccine after removal of antisubstrate cell antibodies.

Authors:  S Giannecchini; D Del Mauro; D Matteucci; M Bendinelli
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Feline leukemia and feline immunodeficiency virus in Canada - A comment.

Authors:  Ed Doornenbal; Walt Ingwersen; Guillaume Cloutier
Journal:  Can Vet J       Date:  2012-01       Impact factor: 1.008

3.  Kinetics of replication of a partially attenuated virus and of the challenge virus during a three-year intersubtype feline immunodeficiency virus superinfection experiment in cats.

Authors:  M Pistello; D Matteucci; G Cammarota; P Mazzetti; S Giannecchini; D Del Mauro; S Macchi; L Zaccaro; M Bendinelli
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

4.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: detailed analysis of the humoral immune response to a protective vaccine.

Authors:  P Mazzetti; S Giannecchini; D Del Mauro; D Matteucci; P Portincasa; A Merico; C Chezzi; M Bendinelli
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

5.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblasts.

Authors:  Simone Giannecchini; Patrizia Isola; Olimpia Sichi; Donatella Matteucci; Mauro Pistello; Lucia Zaccaro; Daniela Del Mauro; Mauro Bendinelli
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

6.  Patterns of feline immunodeficiency virus multiple infection and genome divergence in a free-ranging population of African lions.

Authors:  Jennifer L Troyer; Jill Pecon-Slattery; Melody E Roelke; Lori Black; Craig Packer; Stephen J O'Brien
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

7.  Mutations in the feline immunodeficiency virus envelope glycoprotein confer resistance to a dominant-negative fragment of Tsg101 by enhancing infectivity and cell-to-cell virus transmission.

Authors:  Benjamin G Luttge; Prashant Panchal; Vinita Puri; Mary Ann Checkley; Eric O Freed
Journal:  Biochim Biophys Acta       Date:  2013-09-10

Review 8.  FIV Gag: virus assembly and host-cell interactions.

Authors:  Benjamin G Luttge; Eric O Freed
Journal:  Vet Immunol Immunopathol       Date:  2009-10-14       Impact factor: 2.046

Review 9.  Current progress in the development of a prophylactic vaccine for HIV-1.

Authors:  Lena J Gamble; Qiana L Matthews
Journal:  Drug Des Devel Ther       Date:  2010-12-22       Impact factor: 4.162

Review 10.  Feline immunodeficiency virus (FIV) neutralization: a review.

Authors:  Margaret J Hosie; Daniela Pajek; Ayman Samman; Brian J Willett
Journal:  Viruses       Date:  2011-10-13       Impact factor: 5.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.